Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

2.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

3.

Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH).

Fischer I, de la Cruz C, Rivera AL, Aldape K.

Diagn Mol Pathol. 2008 Dec;17(4):227-30. doi: 10.1097/PDM.0b013e3181642230.

PMID:
18382350
7.
8.
9.

Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.

Peiró G, Aranda FI, Adrover E, Niveiro M, Alenda C, Payá A, Seguí J.

Hum Pathol. 2007 Jan;38(1):26-34. Epub 2006 Oct 23.

PMID:
17056098
10.
11.

Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.

Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chein HP, Lee N, Chen JR.

Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.

PMID:
22092410
12.

Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study.

Yoo SB, Lee HJ, Park JO, Choe G, Chung DH, Seo JW, Chung JH.

Lung Cancer. 2010 Mar;67(3):301-5. doi: 10.1016/j.lungcan.2009.05.002. Epub 2009 Jun 7.

PMID:
19505745
13.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120
14.

Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.

Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM.

Clin Cancer Res. 2004 Jul 15;10(14):4793-8.

15.

Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.

Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D.

Pathol Int. 2005 Jun;55(6):318-23.

PMID:
15943788
17.
18.

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma.

Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR.

Mod Pathol. 2007 Oct;20(10):1028-35. Epub 2007 Aug 3.

19.

HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.

Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, Rey M.

Breast. 2006 Aug;15(4):519-27. Epub 2005 Nov 14.

PMID:
16290155

Supplemental Content

Support Center